Alain Bitton

Alain Bitton

Auto-generated profile, based on publicly available information

Alain Bitton

Division of Gastroenterology, McGill University Health Centre, Montreal, Quebec, Canada

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2001 in Gastroenterology
Verified
Journal Article
Open access
PDF file
ABAlain Bitton
Alain Bitton
MPMark A. Peppercorn
Mark A. Peppercorn
DADonald A. Antonioli
Donald A. Antonioli
JNJohn L. Niles
John L. Niles
SSSamir Shah
Samir Shah
ASAnthony C. Stevens
Anthony C. Stevens
Background & Aims: Ulcerative colitis (UC) is a chronic relapsing infammatory bowel disease. We aimed to assess whether clinical, biological, and histologic parameters in quiescent UC predict time to clinical relapse. Methods: Seventy-four patients with clinically and endoscopically determined inactive UC were followed up for 1 year or for a shorter period if they had a relapse. Serum erythrocyte sedimentation rate; C-reactive protein, interleukin (IL)-1β, IL-6, and IL-15 values; anti-neutrophil cytoplasmic antibody titers; and rectal biopsy specimens were obtained at baseline, at 6 and 12 months, and/or at relapse. Multivariate survival analysis was performed to determine independent predictors of clinical relapse. Results: Twenty-seven patients relapsed (19/42 women; 8/32 men). Multivariate Cox regression analysis retained younger age (P = 0.003; hazard ratio, 0.4 per decade), greater number of prior relapses in women (P < 0.001; hazard ratio, 1.6 per prior relapse), and basal plasmacytosis (P = 0.003; hazard ratio, 4.5) on rectal biopsy specimens as predictors of shorter time to clinical relapse. Kaplan–Meier survival curves showed the 20–30-year-old age group and women with more than 5 prior relapses to be groups with shorter times to relapse. Conclusions: Younger age, multiple previous relapses (for women), and basal plasmacytosis on rectal biopsy specimens were independent predictors of earlier relapse. These findings may help identify patients with inactive UC who will require optimal maintenance medical therapy.

7 April 2008 in Gut
Verified
Journal Article
Closed access
PDF file
ABA Bitton
A Bitton
PDP L Dobkin
P L Dobkin
MEM D Edwardes
M D Edwardes
MSM J Sewitch
M J Sewitch
JMJ B Meddings
J B Meddings
GWG E Wild
G E Wild
Background: Crohn’s disease (CD) is a chronic relapsing inflammatory bowel disorder. Both biological and psychosocial factors may modulate the illness experience. Aim: The aim of this study was to identify clinical, biological and psychosocial parameters as predictors of clinical relapse in quiescent CD. Methods: Patients in medically induced remission were followed prospectively for 1 year, or less if they relapsed. Disease characteristics were determined at baseline. Serum cytokines, anti- Saccharomyces cerevisiae antibodies, C-reactive protein (CRP), erythrocyte sedimentation rate and intestinal permeability were measured every 3 months. Psychological distress, perceived stress, minor life stressors and coping strategies were measured monthly. A time-dependent multivariate Cox regression model determined predictors of time to relapse. Results: 101 patients (60 females, 41 males) were recruited. Fourteen withdrew and 37 relapsed. CRP (HR = 1.5 per 10 mg/l, 95% CI 1.1 to 1.9, p = 0.007), fistulising disease (HR = 3.2, 95% CI, 1.1 to 9.4, p = 0.04), colitis (HR = 3.5 95% CI 1.2 to 9.9, p = 0.02) and the interaction between perceived stress and avoidance coping (HR = 7.0 per 5 unit increase for both scales, 95% CI 2.3 to 21.8, p = 0.003) were predictors of earlier relapse. Conclusions: In quiescent CD, a higher CRP, fistulising disease behaviour and disease confined to the colon were independent predictors of relapse. Moreover, patients under conditions of low stress and who scored low on avoidance coping (ie, did not engage in social diversion or distraction) were least likely to relapse. This study supports a biopsychosocial model of CD exacerbation.

1 February 2012 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
ABAlain Bitton
Alain Bitton
DBDonald Buie
Donald Buie
RERobert Enns
Robert Enns
BFBrian G Feagan
Brian G Feagan
JJJennifer L Jones
Jennifer L Jones
RPRemo Panaccione
Remo Panaccione
The American Journal of Gastroenterology is published by Nature Publishing Group (NPG) on behalf of the American College of Gastroenterology (ACG). Ranked the #1 clinical journal covering gastroenterology and hepatology*, The American Journal of Gastroenterology (AJG) provides practical and professional support for clinicians dealing with the gastroenterological disorders seen most often in patients. Published with practicing clinicians in mind, the journal aims to be easily accessible, organizing its content by topic, both online and in print. www.amjgastro.com, *2007 Journal Citation Report (Thomson Reuters, 2008)

1 February 2016 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
ABAlain Bitton
Alain Bitton
MVMaria Vutcovici
Maria Vutcovici
MSMaida Sewitch
Maida Sewitch
SSSamy Suissa
Samy Suissa
PBPaul Brassard
Paul Brassard
Background. Mortality rates greater than in the general population have been reported in the population with Crohn's disease (CD), but reports for ulcerative co

1 October 2014 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
ABAlain Bitton
Alain Bitton
MVMaria Vutcovici
Maria Vutcovici
VPValérie Patenaude
Valérie Patenaude
MSMaida Sewitch
Maida Sewitch
SSSamy Suissa
Samy Suissa
PBPaul Brassard
Paul Brassard
Background. Among 10 provinces in Canada, Québec has the second highest incidence of Crohn's disease (CD), based on data collected more than a decade ago. To da

1 June 2023 in Journal of the Canadian Association of Gastroenterology
Verified
Journal Article
Open access
PDF file
JWJoseph W Windsor
Joseph W Windsor
MKM Ellen Kuenzig
M Ellen Kuenzig
SMSanjay K Murthy
Sanjay K Murthy
ABAlain Bitton
Alain Bitton
CBCharles N Bernstein
Charles N Bernstein
GKGilaad Kaplan
Gilaad Kaplan
The burden of inflammatory bowel disease (IBD) (i.e., associated direct and indirect costs, prevalence of disease, personal impact to the individual and to caregivers) continues to increase in Canada. The prevalence of IBD has increased since Crohn’s and Colitis Canada’s 2018 Impact of IBD report from an estimated 270,000 Canadians living with IBD in 2018 to an estimated 322,600 Canadians living with IBD today in 2023. Consequently, associated costs of IBD have also dramatically increased from an estimated $2.57 billion in 2018 to an estimated $5.38 billion in 2023; this increase is due to multiple factors including increased prevalence of disease, inflation, and additional identified factors (e.g., presenteeism, costs of childcare). Beyond the economic impact of IBD, these diseases have a significant impact on people living with the disease and their caregivers, including different presentations of disease, different commonly associated extra-intestinal manifestations or comorbid conditions, and different barriers to accessing care. In this supplementary issue, we review: Evolving trends in the epidemiology of IBD; updated estimates of indirect and direct costs (including out-of-pocket costs) associated with IBD; information specific to IBD in children, adolescents, and seniors; issues related to IBD pertaining to sex and gender; information specific to risks associated with COVID-19 and cancer related to IBD; an overview of current treatments for IBD; and evolving care models, including access to care.